TY - JOUR
T1 - Neuroendocrine (Small-cell) carcinomas
T2 - Why they teach us essential lessons about prostate cancer
AU - Aparicio, Ana
AU - Tzelepi, Vassiliki
N1 - Publisher Copyright:
© 2014 American College of Radiology.
PY - 2014/10/15
Y1 - 2014/10/15
N2 - Atypical clinical features in men with prostate cancer—such as clinical evidence of disease progression in the absence of a proportional increase in serum prostate-specific antigen level, bulky symptomatic tumor masses, exclusive visceral metastases, or a predominance of lytic bone metastases—should alert the clinician that an aggressive prostate cancer variant is present or emerging. Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies. Indeed, the finding of neuroendocrine or small-cell prostate carcinoma indicates the need for multimodality treatments that incorporate early combination chemotherapy and locoregional control of bulky tumor deposits, including untreated or recurrent primaries. As we learn to recognize this prostate cancer variant more often, we are reminded that not all prostate cancers share the same biology and that the androgen receptor is not the sole driver of this disease.
AB - Atypical clinical features in men with prostate cancer—such as clinical evidence of disease progression in the absence of a proportional increase in serum prostate-specific antigen level, bulky symptomatic tumor masses, exclusive visceral metastases, or a predominance of lytic bone metastases—should alert the clinician that an aggressive prostate cancer variant is present or emerging. Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies. Indeed, the finding of neuroendocrine or small-cell prostate carcinoma indicates the need for multimodality treatments that incorporate early combination chemotherapy and locoregional control of bulky tumor deposits, including untreated or recurrent primaries. As we learn to recognize this prostate cancer variant more often, we are reminded that not all prostate cancers share the same biology and that the androgen receptor is not the sole driver of this disease.
UR - http://www.scopus.com/inward/record.url?scp=84910068141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910068141&partnerID=8YFLogxK
M3 - Article
C2 - 25323607
AN - SCOPUS:84910068141
SN - 0890-9091
VL - 28
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 10
ER -